Korro Bio Doses First Patients in Phase 1/2 Trial for Rare Disease Therapy

  • Korro Bio dosed the first cohort in its Phase 1/2 ANCHOR trial for KRRO-121, a GalNAc-conjugated RNA-editing oligonucleotide targeting hyperammonemia in urea cycle disorders (UCDs) and hepatic encephalopathy (HE).
  • The trial began with healthy volunteers in Australia, with UCD patient dosing expected to start in early 2027 and interim results anticipated in late 2027.
  • KRRO-121 aims to provide a pan-UCD treatment, potentially reducing ammonia levels and lowering the risk of hyperammonemic crises.
  • The ANCHOR trial consists of two parts: a Phase 1 single and multiple ascending dose study in healthy volunteers, and a Phase 2 trial in UCD patients.

Korro Bio’s advancement into clinical trials for KRRO-121 marks a critical step in developing a first-in-class therapy for hyperammonemia, a condition with limited treatment options. The OPERA platform’s ability to deliver precise RNA edits could redefine genetic medicine, particularly for rare metabolic disorders. Success in this trial would not only validate Korro’s technology but also position it as a key player in the growing RNA-editing space.

Clinical Efficacy
Whether KRRO-121 can demonstrate meaningful ammonia control in UCD patients, validating its preclinical promise.
Regulatory Pathway
The pace at which Korro secures regulatory approvals for broader UCD patient enrollment and subsequent trials.
Market Differentiation
How KRRO-121’s potential for infrequent subcutaneous dosing positions it against existing treatments for UCDs and HE.